Company intelligence / Profile preview

Siam Bioscience Co., Ltd.

Pathum Wan, Bangkok, Thailandsiambioscience.com ↗

Ownership: Private
Employees: ~125
Development stage: Commercial

Overview

Siam Bioscience has successfully launched both their own pipeline products and partners' products via technology transfer. They began commercial operations in 2016, producing two biopharmaceuticals: one for treating anemia in patients with kidney failure, and another for reducing the risk of infection among cancer patients receiving chemotherapy.

Therapeutic areas: OncologyNephrology
Modalities: BiopharmaceuticalsCell and gene therapy (CGT)Advanced therapy medicinal products (ATMPs)OligonucleotidesBispecific monoclonal antibodiesAntibody-drug conjugates (ADCs)
Industry: Biotech

Drug pipeline

1 asset

SBS6002

Unknown

Partnerships

AstraZeneca (COVID-19 vaccine production)CIMAB S.A. (Cuba)Mahidol University

Beyond the preview

Go deeper on Siam Bioscience Co., Ltd..

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Siam Bioscience Co., Ltd..

Explore the full profile